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Perspectives
In recent years, pharmaceutical com-
panies have introduced new expensive 
medicines, some of which target only 
small patient populations. For example, 
trastuzumab (Herceptin®), imatinib 
(Glivec®) and sofosbuvir (Sovaldi®) are 
high-priced medicines that have been 
shown to be effective and safe for treat-
ing cancer or hepatitis C, diseases for 
which no effective treatment existed 
previously. In 2015, the World Health 
Organization included several such 
expensive medicines in their model list 
of essential medicines,1 despite current 
prices of 60 000–100 000 United States 
dollars per treatment. The initial public 
enthusiasm for these medicines’ thera-
peutic value is now tempered by practi-
cal concerns about how patients and 
health systems can afford them. Even in 
high-income countries the affordability 
is a concern.
Ethical and economic dilemmas 
arise when decision-makers must ra-
tion an expensive, life-saving or life-ex-
tending medicine. We contend that not 
funding an effective essential medicine 
contradicts Article 12 in the Interna-
tional Covenant on Economic, Social 
and Cultural Rights, which declares 
“the States Parties to the present 
Covenant recognize the right of ev-
eryone to the enjoyment of the highest 
attainable standard of physical and 
mental health.” 
By September 2016, over 160 coun-
tries have ratified or acceded to the 
Covenant.2 In many countries, such as 
Argentina, Brazil, Latvia, New Zealand 
and Uruguay, patients have used Article 
12 to litigate through domestic courts 
for the reimbursement of expensive 
medicines.3 In the Netherlands, advo-
cates of patients with Pompe’s disease 
– a rare muscle disease – based part of 
their arguments on the fact that it was 
the patients’ right to receive continued 
reimbursement of an expensive treat-
ment with marginal health benefits. 
Decision-makers decided to continue 
reimbursement, despite the fact that 
many other patients in the country were 
not reimbursed for more cost–effective 
treatments.
How can governments with finite 
public health budgets ensure fair access 
to expensive, new and essential medi-
cines as part of the right to health? Is 
the right to health equally important 
for all patients?
Governments’ efforts to prioritize 
access to essential medicines could be 
supported by a human rights approach 
and specifically by the principle of the 
progressive realization of the right to 
health.2 The United Nations Commit-
tee on Economic, Social and Cultural 
Rights describes progressive realization 
as States Parties’ obligation to use the 
maximum of its available resources to 
move as expeditiously and effectively as 
possible towards achieving the highest 
attainable standard of health for every-
one.2,4 The approach does not necessarily 
create an immediate right for everyone 
to receive treatment at any cost. Instead, 
progressive realization means that access 
to health care is gradually fulfilled for all 
patients. All Parties have an immediate 
obligation to take deliberate, concrete 
and targeted steps towards progressive 
realization.5 However, providing im-
mediate universal health care with all 
possible treatments for all people is not 
a legal obligation.5
For prioritization, a transparent and 
independent reimbursement ranking 
process of medical treatments, largely 
based on estimates of comparative 
cost–effectiveness, presents a concrete 
and practical tool for decision-makers. 
Progressive realization justifies such 
ranking of treatments by ensuring that 
governments use available resources 
as effectively as possible and thereby 
progressively realizing the right to 
health for the largest number of people 
at the lowest possible cost and without 
discrimination against patients. This 
duty of efficiency is also in line with the 
authoritative interpretation by the Com-
mittee on Economic, Social and Cultural 
Rights of governments’ legal obligations 
under the human rights treaties in 
General Comment 3, as well as a well-
founded set of principles adopted by a 
group of scholars and policy-makers in 
the Limburg Principles.4,6
Progressive realization also presents 
a human rights justification for not re-
imbursing certain treatments, thereby 
protecting fair reimbursement decisions 
from being derailed by patients claiming 
very expensive treatments based on their 
individual right to health, in the absence 
of other criteria, such as comparative 
cost–effectiveness. An argument to 
claim reimbursement of very expensive 
treatments is that patients with rare dis-
eases are disadvantaged because fewer 
patients need to cover the development 
costs of the medicine. In 2005, Mc-
Cabe et al. reviewed and dismissed this 
argument. They based their arguments 
on the fact that the public sector often 
already invests substantially in orphan 
drug development.7 Furthermore, the 
authors questioned whether the public 
sector should also subsidize the private 
sector to develop orphan medicines that 
will cost society more than the health 
benefits to be gained. From a human 
rights perspective, the key message to 
those patients is that their right to health 
is recognized, but that it can only be ful-
filled in the future. The fact that a disease 
is rare is, in itself, not a justification for 
unlimited reimbursement.
To accelerate progressive realization 
and increase the number of patients 
that are eligible for reimbursement, 
governments could increase their health 
budgets, an action supported by the 
Parties’ obligation to use the maximum 
of their available resources.2 A much 
more effective way to realize the right to 
health would be through targeted gov-
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ernment action using all available tools 
to reduce prices, such as the flexibilities 
to the Agreement on trade-related aspects 
of intellectual property rights.8 Some 
new medicines, such as antiretroviral 
therapy, were initially marketed at very 
high prices but became much cheaper 
after targeted price-reduction actions 
from governments.9
Pharmaceutical companies and 
their shareholders also have a duty 
under human rights law to ensure that 
their new products are made available 
and affordable to all who need them.10 
They should, therefore, refrain from 
actions that limit accessibility, such as 
pursuing stronger intellectual property 
protection, and should, within a viable 
business model, ensure that new medi-
cines are accessible to all those in need.10 
In addition, the publication Guiding 
Principles on Business and Human 
Rights advocates that companies respect 
the right to health and access to medi-
cines.11 Companies’ violations of these 
human rights principles give national 
governments a justification to impose 
corrective measures, such as compulsory 
licencing for cheaper domestic produc-
tion. For example, the anti-cancer drug 
sorafenib tosylate (Nexavar®) from Bayer 
is now produced in India at a more af-
fordable price because of a compulsory 
licence issued by the government.12
Finally, a transparent and indepen-
dent reimbursement ranking process is 
important to show that all patients are 
treated equally and without discrimina-
tion. The process should adopt explicit 
criteria, such as comparative cost–ef-
fectiveness, severity of the disease or 
end-of-life care, which should be based 
on standards set independently of the 
pharmaceutical industry. The weight 
of these criteria in the ranking process 
should be established in consultation 
with beneficiaries and the criteria 
should be adjudicated consistently. 
Such transparent decision-making can 
inspire meaningful and balanced public 
consultation and can better inform the 
public debate on trade-offs during the 
ranking process.13 Such transparency 
also promotes greater accountability of 
governments for their reimbursement 
decisions. The use of the Accountabil-
ity for Reasonableness Framework can 
further guide the fair rationing of health 
care.14 ■
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